title: Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study.
abstract: BACKGROUND
  Ligands of nuclear hormone receptors such as glucocorticoid, retinoid and vitamin D are useful antipsoriatic drugs. Peroxisome proliferator-activated receptors (PPARs), which also belong to the nuclear hormone receptor superfamily, are pleiotropic regulators of growth and differentiation in many cell types, including the keratinocytes. Recent reports have dealt with the involvement of PPARalpha in epidermal processes such as barrier development, proliferation and differentiation. In a pilot study of topical clofibrate, a PPARalpha ligand, we did not find any antipsoriatic activity. No study on the effect of topical application of other PPAR subtype ligands (PPARbeta/delta and gamma) has been published.
  
  
  OBJECTIVE
  The purpose of this pilot study is to explore the clinical efficacy of the topical application of potent PPARbeta/delta and gamma agonists on plaque psoriasis, tetradecylthioacetic acid (TTA) and rosiglitazone, respectively.
  
  
  METHODS
  In a pilot study on psoriatic patients, 8 individuals (5 male/3 female) were treated twice daily for 30 days with vehicle (n = 14 plaques), rosiglitazone 0.5% (n = 18) and TTA 0.5% (n = 18). Assessments of the PASI plaque score were carried out on days 0, 4, 7, 11, 14 and 30.
  
  
  RESULTS
  No statistically significant difference was found at any of the examination times, between vehicle, rosiglitazone and TTA in terms of reduction of the PASI plaque score for total, scale and infiltration scores. Treatments were well tolerated, and skin irritation, adverse drug-related symptoms and dropouts did not occur.
  
  
  CONCLUSIONS
  With the reservations due to the limited nature of this pilot trial, it seems that these topical PPARbeta/delta and gamma agonists do not exert a strong antipsoriatic effect when used alone at 0.5%.
authors.affiliation: Department of Dermatology, University of Geneva, Switzerland. s.kuenzli@infomaniak.ch
authors.forename: Stéphane
authors.initials: S
authors.lastname: Kuenzli
authors.forename: Jean-Hilaire
authors.initials: JH
authors.lastname: Saurat
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011565:Psoriasis / Q000188:drug therapy*; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists*; D000077154:Rosiglitazone; D013440:Sulfides / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000819:agonists*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D016166:Free Radical Scavengers; D018160:Receptors, Cytoplasmic and Nuclear; D013440:Sulfides; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D014665:Vasodilator Agents; D000077154:Rosiglitazone; C062078:1-(carboxymethylthio)tetradecane